Aethlon Medical, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023
June 28, 2023 at 04:15 pm EDT
Share
Aethlon Medical, Inc. reported earnings results for the full year ended March 31, 2023. For the full year, the company reported net loss was USD 12.03 million compared to USD 10.42 million a year ago. Basic loss per share from continuing operations was USD 5.9 compared to USD 7.1 a year ago.
Aethlon Medical, Inc. (Aethlon) is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections suppression, seed the spread of metastasis and inhibit the benefit of cancer therapies. The Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression. Hemopurifier helps to bind and clear multiple different glycosylated viruses, such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), Dengue, West Nile, multiple strains of influenza, Ebola, Chikungunya, smallpox, monkeypox, multiple herpes viruses, a MERS-CoV related pseudovirus, and others. Hemopurifier is used as a device for two independent indications: the treatment of individuals with advanced or metastatic cancer and the treatment of life threating viruses that are not approved therapies.